Search
The Deal magazine looks at the biotech sector and how new, creative funding deals are promising to rejuvenate the search for new drugs. Plus, this issue looks at LIBOR's new landscape. Meanwhile, we have an indepth conversation with CD&R's Joseph Rice.
June 18, 2012What goes up must come down, and so it would appear as The Deal magazine examines big-league bankruptcy. The theory holds for Tribune as it's new owners weigh its assets. But what about W.R. Grace, as it emerges from bankruptcy having made 22 acquisitions under protection? Plus, the corporate dealmaker 100.
May 28, 2012The Deal magazine takes an indepth look at the strategic dealmaking of the packaging industry in the middle market. We also hit the road looking at the startup landscape in the drug development and medical devices sectors in Kalamazoo, Michigan as well as the burgeoning companies in the solar power, pharmaceutical, brewery and pesticide industries in Bend, Oregon.
May 7, 2012Wanna do M&A? Careful, because here comes the shareholder litigation. When it comes to tech acquisitions, they're getting done -- just too bad companies aren't very good at it. And sovereign wealth funds are back, growing fast.
April 16, 2012No one said private equity would be easy, and our annual Private Equity Deals of the Year proves it again with a roundup of 2011's big winners and losers. Also, The Deal magazine takes a look at cowboy capitalism with a trip to Dallas-Fort Worth. Finally, take a look at our sampling of middle-market companies on the auction block.
April 2, 2012The Deal magazine travels to Japan to witness the island nation rise again amidst an active streak of dealmaking. Plus, a duet of music-related articles look at the antitrust snares of Universal Music's purchase of EMI assets and the effect that the emergence of digital music is having on copyright laws.
March 12, 2012In this issue, The Deal magazine hits the bankruptcy trifecta: the take-no-prisoners battle for Alter Communications; the rise and fall of real estate moguls, the Meruelo brothers; and the bankruptcy league tables. Also, take a look at how Humana has set a new course along the acquisition trail.
February 20, 2012The Deal magazine focuses on the middle market by looking at some of its top dealmakers and then gives an overview of what's out there on the auction block. The issue also features an in-depth look at private equity in France and in emerging markets around the world.
February 6, 2012The Deal magazine gets in the pilot seat to take a look at American Airlines' bankruptcy, then wonders what will now happen to a beleaguered Reader's Digest. Also, Herb Fritch of HealthSpring may have an answer to the sky-high inflation of the healthcare industry.
January 23, 2011What a topsy-turvy, rumbly-tumbly year 2011 turned out to be -- and The Deal magazine takes a look at the M&A Deals of the Year in uncertain times. Also, Edgar Bronfman Jr. sits down for his first interview since selling Warner Music.
December 12, 2011Just when you thought it was safe to go back in the water, suddenly it was 2011 -- and The Deal magazine looks back at all the twists and turns of dealmaking. Also in this issue, dealmakers pay back as social entrepreneurs.
November 28, 2011'What worrying wall of debt?' The Deal magazine asks. Oh, right, there it is. Plus, the Windy City offers up its own particular brand of private equity, while, farther afield, Big Oil makes a play in Kurdistan.
November 14, 2011The Deal magazine tracks down the in-house corporate dealmakers from the top American companies and takes a voyage around the world to explore the valleys and peaks of the travel industry.
October 31, 2011The Deal magazine goes back to school and offers a full report on the business of education.
October 17, 2011The Deal magazine goes looking for trolls and geeks, and the middle market shows its ups and downs in a trying economy.
October 3, 2011Who are the private equity movers and shakers to keep an eye on, and how does Ralph de la Torre look to transform managed care?
September 19, 2011The Deal magazine honors this year's Most Admired Corporate Dealmakers and takes a close look at the ups and downs of Wall Street compensation.
September 5, 2011The interview issue asks all the pertinent questions to six experts in their respective fields, while the market for multiple sclerosis therapies provides an evocative case study on dealmaking.
July 25, 2011The Deal magazine gets up close and personal with faces of the middle market and charts the new hits of the music business as it shifts away from label dominance.
June 27, 2011Despite trying financial times, the spotlight shines on the private equity deals of the year that were deftly executed and held to the principle of creating value.
Robert Dentice, managing director and co-head of Cantor Fitzgerald & Co.'s healthcare investment banking unit predicts that healthcare content companies with diagnostic tests that aid in personalized medicine will become hot M&A targets for drugmakers and other life sciences companies.
The Deal Pipeline?s David Marcus and Skadden Arps' Charles Schwartz discuss how multijurisdictional litigation plays out in energy deals in Texas, as well as the legacy of Texaco-Pennzoil on cases filed in Texas.
Rare historical documents, from presidential letters to the Emancipation Proclamation, are attracting collectors looking for valuable pieces of Americana at relatively low prices. But the market is heating up.
The retiring chairman sat down to discuss his career, the evolution and future of the PE industry and his work with the Private Capital Research Institution.
A familiar cast of characters bellies up to the bar to advise Anheuser-Busch InBev, while Marathon falls prey to the Greek crisis.
As politicians point fingers at each other, the furor over the banks' manipulation has unleashed new pressures for change.
Basing the rate on actual transaction costs will improve transparency but increase volatility.
IVP's Jules Maltz discusses his firm's new billion-dollar fund and the state of the venture industry.
Hirings, defections and the arts.
The British prime minister's austerity policies continue to misfire, the euro zone continues to shudder, and the News Corp. hacking scandals continue to unfold.
New, creative financing deals among financiers, big pharmas and biotech entrepreneurs are promising to rejuvenate the search for new drugs.
Poland, Hungary and Romania remain linked to the euro zone but retain their own currencies. This makes for both anxiety and optimism.
Turkey's largest private equity firm isn't large by Western standards, but it's riding a fast-growing economy between Europe and Asia.
U.S. corporates and their in-house dealmakers are still learning how to navigate acquisitions in China. Rule No. 1: Be patient.
Defining LIBOR and its role in the latest financial scandal.
Despite great efforts, the U.S. has yet to develop a true archvillain of the financial crisis. The Brits, on the other hand, now have bubbly-swilling, rate-rigging Bob Diamond. It's why they have tabloids.
We run the numbers on a tax-free spinout of Mel Karmazin's radio satellite company, the Atlanta Braves and who knows what else orchestrated by the geniuses at Liberty Media. Will it fly? We'll see.
A task force reveals what's needed to attract more cases to the Empire State: a lot more resources.
Most banks are conforming to new Financial Accounting Standards Board rules for federal guarantees on loan losses. Others aren't.
With market conditions more tumultuous than earlier in the year, banks are more frequently seeking looser flex terms as they try to ensure that loans are attractive to investors.
It's not easy, but Apax proved that you can negotiate arcane delisting rules to pull off a complex private equity–funded transaction.
Several investment themes within the space are poised to present attractive opportunities for private equity investors.
When it comes to making representations and warranties, timing can be everything.
Here are the issues English courts will ask about such cases.
